SEOUL, SK Biopharmaceuticals Co. on Monday reported its 2023 net loss of 36.3 billion won (US$27.2 million), remaining in the red compared with the previous year. The company said in a regulatory filing that it continued to post an operating loss of 37.1 billion won for the year, compared with a loss of 131.1 billion won a year earlier. Revenue rose 44.2 percent to 354.9 billion won. Source: Yonhap News Agency
Myanmar Clears Path for Junta Leader to Become President
March 30, 2026